Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.55
+1.1%
$0.59
$0.21
$0.82
$594.28M0.331.25 million shs1.87 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.67
-4.5%
$4.30
$2.45
$6.71
$592.43M1.761.43 million shs927,215 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$22.68
-2.7%
$19.39
$11.56
$29.79
$582.65M2.04285,454 shs84,753 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%+1.18%-0.54%+3.68%+174.31%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+3.38%-2.78%+68.62%+66.89%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
0.00%+3.28%+17.91%+52.15%+47.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.5188 of 5 stars
0.03.00.00.02.80.80.0
Organogenesis stock logo
ORGO
Organogenesis
3.8358 of 5 stars
3.31.00.04.30.04.20.6
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.3362 of 5 stars
3.52.00.00.02.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5060.60% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$50.14121.09% Upside

Current Analyst Ratings Breakdown

Latest PTNT, ORGO, ELTP, and TRML Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00
8/14/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.07$0.02 per share32.00$0.05 per share11.10
Organogenesis stock logo
ORGO
Organogenesis
$429.31M1.38$0.20 per share23.43$2.09 per share2.23
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32M-$0.01N/AN/A-10.26%-9.88%-4.72%11/13/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)

Latest PTNT, ORGO, ELTP, and TRML Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2026
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A-$0.01N/A-$0.01N/A$40.21 million
8/13/2025Q2 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.94-$0.90+$0.04-$0.90N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.09
7.23
5.44
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
24.68
24.68

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion916.53 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.69 million22.35 millionOptionable

Recent News About These Companies

FY2025 EPS Estimates for Tourmaline Bio Lowered by Analyst
Leerink Partnrs Expects Higher Earnings for Tourmaline Bio
Tourmaline Bio Q3 EPS Estimate Raised by Lifesci Capital
Wedbush Estimates Tourmaline Bio's Q3 Earnings (NASDAQ:TRML)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.55 +0.01 (+1.09%)
As of 03:58 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.67 -0.22 (-4.50%)
Closing price 04:00 PM Eastern
Extended Trading
$4.71 +0.04 (+0.86%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$22.68 -0.63 (-2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$21.99 -0.69 (-3.04%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.